Physician profile
John Warwick
NPI 1730286865
$1,915.06
in general payments reported to CMS, 2019-2025
24 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.30 · 2020: $149 · 2021: $355 · 2022: $304 · 2023: $439 · 2024: $338 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $330.92 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $239.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $179.88 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $143.50 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.90 | 2021-2023 | Eliquis |
| Abbvie INC. | $129.42 | 2021-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $96.46 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.89 | 2022-2023 | Xarelto |
| Abbott Laboratories | $86.95 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.43 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $71.70 | 2021-2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $52.38 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.42 | 2021-2024 | Jardiance |
| Amgen INC. | $39.43 | 2021-2022 | |
| Medtronic, INC. | $30.92 | 2024 | Venaseal |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.99 | 2020 | |
| Seqirus USA INC | $22.75 | 2025 | Fluad, Flucelvax |
| Eisai INC. | $22.22 | 2025 | |
| Nestle Healthcare Nutrition INC. | $21.88 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.95 | 2024 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $15.39 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Warwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.